PROTEIN STRUCTURE AND FOLDING
Identification of Amino Acid Residues in Bone Morphogenetic Protein-1 Important for Procollagen C-proteinase Activity*

https://doi.org/10.1074/jbc.M010814200Get rights and content
Under a Creative Commons license
open access

Bone morphogenetic protein (BMP)-1, which belongs to the tolloid subgroup of astacin-like zinc metalloproteinases, cleaves the C-propeptides of procollagen at the physiologic site and is, therefore, a procollagen C-proteinase (PCP). Cleavage occurs between a specific alanine or glycine residue (depending on the procollagen chain) and an invariant aspartic acid residue in each of the three chains of procollagen. To learn more about how BMP-1 exhibits PCP activity we mapped the primary structure of BMP-1 onto the x-ray crystal structure of astacin and identified residues in the metalloproteinase domain of BMP-1 for subsequent site-directed mutagenesis studies. Recombinant wild-type and mutant BMP-1 were expressed in COS-7 cells and assayed for PCP activity using type I procollagen as the substrate. We showed that substitution of alanine for Glu94, which occurs in the HEXXH zinc-binding motif of BMP-1, abolishes PCP activity. Furthermore, mutation of residues Lys87 and Lys176, which are located in the S1′ pocket of the enzyme and are therefore adjacent to the P1′ residue in the substrate, reduced the proteolytic activity of BMP-1 by ∼50%. A surprising observation was that mutation of Cys66 reduced the activity to 20%, suggesting that this residue is crucial for activity. Further experiments showed that Cys66 and Cys63, which are located in the tolloid-specific sequence Cys63-Gly64-Cys65-Cys66in the active site, most likely form a disulfide bridge.

Cited by (0)

Published, JBC Papers in Press, March 29, 2001, DOI 10.1074/jbc.M010814200

*

This work was supported by grants from The Wellcome Trust (019512 and 012578) and from AstraZeneca (Alderley Edge, Macclesfield, Cheshire, United Kingdom). The studies detailed in this paper were performed in the Wellcome Trust Centre for Cell-Matrix Research, which was established by Wellcome Trust Grant 040450/Z/94/Z.The costs of publication of this article were defrayed in part by the payment of page charges. The article must therefore be hereby marked “advertisement” in accordance with 18 U.S.C. Section 1734 solely to indicate this fact.